Kidney risk is hiding in data you already collect. NephroSense AI reads it.
Routine panels already drawn carry a signal the creatinine threshold cannot see. One platform surfaces it — prioritizing patients for confirmatory kidney testing in the clinic, and characterizing candidate populations for retrospective research.
Routine records. Nothing flagged.
- Inputs
- Values already present in a routine adult workup — standard blood work, vitals and basic history, drawn and recorded as part of ordinary care.
- Evidence
- Retrospective feasibility demonstrated on a US adult clinical cohort. Independent external validation is in progress and is not yet complete.
- IP
- Patent-pending technology. Provisional patent filed March 2026.
One Platform, Two Channels
One platform foundation. Separate models, workflows, and evidence paths.
Health systems ask who should be prioritized for confirmatory kidney testing. Research sponsors ask what routine records hold that a site query misses.
Biopharma Research · near-term focus
STRATA
Open for sponsor collaborationCohort construction for kidney and cardio-renal programs
Estimate the candidate population a site actually holds before you select it, rather than after.
For Clinical operations · Feasibility · Clinical development · Medical affairs
Health Systems · clinical foundation
VANTAGE
Available todayCKD risk triage from the panel you already drew
Risk triage at the point of care.
For Clinicians, primary care groups, FQHCs
Problem → Solution Matrix
The Signal Is Already in Your Labs. We Surface It.
NephroSense AI connects unconnected routine lab results into actionable, explainable risk triage.
People affected worldwide
Silent until late stages
Projected 5th leading cause of death worldwide (ISN/WHO)
Sources: clinical references
Unconnected Routine Labs
Routine bloodwork and vitals are taken regularly, but early subtle trends across multiple biomarkers go unflagged until eGFR drops severely or symptoms emerge.
Late referrals, preventable disease progression, and costly emergency interventions.
Data Already Exists
The clinical signal to surface CKD risk is already present in standard adult primary care bloodwork, metabolic panels, and vitals. The bottleneck is synthesis, not testing.
Extract earlier risk insights without requesting new tests or specialized equipment.
Automated AI Triage
NephroSense AI analyzes routine lab panels in seconds, surfacing explainable risk scores and KDIGO-aligned guidance for physician oversight.
Timely confirmatory testing follow-up and proactive primary care intervention.
3-Step Clinical Workflow
Three Steps. Ten Seconds. Zero New Hardware.
From routine adult lab panels to clinician-ready decision support in under 10 seconds. Built for primary care, FQHCs, and value-based care workflows.
- 01
1. Ingest Routine Adult Bloodwork
No new blood tests. No new hardware.
Input routine adult patient biomarkers manually or upload a lab report (PDF/image). Operates directly on standard blood panels and vitals already present in patient records.
- 02
2. Instant AI Risk Stratification
KDIGO-aligned triage in under 10 seconds.
NephroSense AI returns a CKD risk score from the routine adult panel already on file, with a confidence signal alongside it so the strength of the result is visible before you act on it.
- 03
3. Clinician Review & Action
Actionable guidance for physician oversight.
Receive KDIGO 2024-aligned clinical considerations, referral urgency flags, and downloadable clinician-ready PDF summaries or FHIR R4 exports for early confirmatory testing follow-up.
Clinical Considerations
Nephrology Referral
High-risk CDS flag plus abnormal routine labs warrant expedited physician review
Blood Pressure Optimization
Target < 130/80 mmHg per KDIGO guidelines
Lifestyle Modifications
Dietary sodium restriction and regular physical activity
Illustrative — synthetic data. Not a real patient or a performance claim.
Who It's For
Built for the Clinicians Who Need It Most
NephroSense AI is designed for resource-constrained settings where the need is greatest and the impact highest.
FQHCs & Community Health Centers
Reach underserved populations with existing labs — no new laboratory tests required. Designed for the communities most affected by CKD disparities.
Primary Care Physicians
Surface at-risk patients early with risk scores whose basis is visible to the clinician and KDIGO-aligned clinical considerations, without needing nephrology expertise.
Value-Based Care Programs
Batch screen populations, visualize risk distributions, and prioritize interventions so at-risk patients get confirmatory testing sooner.
Beyond the point of care, NephroSense AI becomes a risk-intelligence layer for the partners who shape how CKD is studied and surfaced.
Pharma & Life Sciences
Cohort construction for kidney and cardio-renal programs. Much of the recruitable population is invisible before it can be ranked. We surface a candidate population from routine panels already in a health system's data — including patients with no CKD diagnosis code and no urine albumin result on file.
Pathology & Diagnostic Labs
Routine results can carry a kidney-risk signal that a single-threshold review does not surface. NephroSense AI returns a risk score and confidence signal from values already present in a routine adult workup.
Clinical Foundation & Governance
Grounded in Evidence, Built for Interoperability
Designed to align with global nephrology guidelines, open EHR interoperability standards, and CDS regulatory pathways.
USA
Clinical Feasibility
Feasibility demonstrated on a US adult clinical cohort
KDIGO
Kidney Disease: Improving Global Outcomes
2024 Clinical Practice Guidelines for CKD
CDS
Routine-Lab Clinical Decision Support
Primary CDS workflow reads a routine adult lab workup. Confirmatory kidney testing follows after a patient is flagged.
FHIR R4
Fast Healthcare Interoperability Resources
HL7 standard for EHR data exchange
Built by Scientists, Physicians & AI Engineers
Deep expertise across clinical oversight, AI engineering, and healthtech scaling.
Dr. Poornima Dubey, PhD
Co-Founder
MIT · HMS · IIT · AI/ML · Nanobiotech · HealthTech
Dr. Nisha, MBBS
Co-Founder
KGMU · Clinical Oversight
Dr. Amit Jain
Co-Founder
CS/AI Engineer
Institutional Ties & Background
Backed by
21st Century Cures Act CDS Pathway
Regulatory Note: NephroSense AI is designed to qualify for the Clinical Decision Support exemption under the 21st Century Cures Act. We have not yet received FDA classification or clearance; regulatory status will evolve as the product advances through clinical validation. The tool provides risk scores and supporting explanations to assist qualified healthcare professionals. It does not provide diagnoses. All clinical decisions require physician review and independent clinical judgment.
Advised by clinical, commercial and regulatory veterans. Meet the advisory board →
Ready to see what your routine data holds?
Start a conversation about a retrospective look-back, or try the clinical demo with built-in scenarios.